Nigeria says finds an H5 strain of bird flu in poultry

Nigeria said on Friday it had quarantined two poultry farms in the north and south of the country after detecting an H5 strain of bird flu in both, giving no further details on the strain. Agriculture Minister Akinwumi Adesina statement said samples were taken from birds at the two farms, in the commercial hub Lagos and the main northern city of Kano, after they showed “unusual high mortality” rates. A spokesman for the ministry was not able to elaborate on the virus strain’s subtype. Nigeria, Africa’s most populous country and biggest economy, was the continent’s first country to detect bird flu in 2006, when chicken farms were found to have the H5N1 strain.
Go to Source

Two volunteers with potential Ebola exposure flown to Britain

Two volunteers with potential exposure to the deadly Ebola virus are being transported to Britain for precautionary monitoring, health officials said on Friday. The volunteers, who had been working with victims of the vast Ebola epidemic in West Africa, would arrive on Friday for assessment, and then be monitored for the rest of a 21-day incubation period, Public Health England (PHE) said. The first volunteer was potentially exposed in Sierra Leone because of damage to personal protective equipment, PHE said, but had no contact with the blood or bodily fluids of any Ebola patient during this time. It did not say where the second had been working, but said this volunteer was being brought to Britain by their employer, a non-governmental organisation, in a private aircraft.
Go to Source

J&J Ebola vaccine gets 100 million euros to speed development

Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe’s Innovative Medicines Initiative to speed development. J&J has been seeking partners after committing up to $200 million to accelerate its Ebola vaccine program in October. The new initiative will see J&J join with institutions including the London School of Hygiene & Tropical Medicine, the University of Oxford and the Institut National de la Sante et de la Recherche Medicale to form consortia working on different aspects of vaccine development. Europe’s Innovative Medicines Initiative (IMI) is a public-private scheme jointly paid for by the European Commission and the pharmaceuticals industry.
Go to Source

1 28 29 30 31 32 59